Noncovalent Complexation of Amphotericin‑B with Poly(α-glutamic acid)

A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20–50%. AmB was in a highly aggregated state with an aggregation ratio often...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular pharmaceutics 2013-03, Vol.10 (3), p.940-950
Hauptverfasser: Mohamed-Ahmed, Abeer H. A, Les, Karolina A, Seifert, Karin, Croft, Simon L, Brocchini, Stephen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 950
container_issue 3
container_start_page 940
container_title Molecular pharmaceutics
container_volume 10
creator Mohamed-Ahmed, Abeer H. A
Les, Karolina A
Seifert, Karin
Croft, Simon L
Brocchini, Stephen
description A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20–50%. AmB was in a highly aggregated state with an aggregation ratio often above 2.0. This complex (AmB–PGA) was shown to be stable and to have reduced toxicity to human red blood cells and KB cells compared to the parent compound; cell viability was not affected at an AmB concentration as high as 50 and 200 μg/mL respectively. This AmB–PGA complex retained AmB activity against intracellular Leishmania major amastigotes in the differentiated THP-1 cells with an EC50 of 0.07 ± 0.03–0.08 ± 0.01 μg/mL, which is similar to Fungizone (EC50 of 0.06 ± 0.01 μg/mL). The in vitro antileishmanial activity of the complex against Leishmania donovani was retained after storage at 37 °C for 7 days in the form of a solution (EC50 of 0.27 ± 0.03 to 0.35 ± 0.04 μg/mL) and for 30 days as a solid (EC50 of 0.41 ± 0.07 to 0.63 ± 0.25 μg/mL). These encouraging results indicate that the AmB–PGA complex has the potential for further development.
doi_str_mv 10.1021/mp300339p
format Article
fullrecord <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_mp300339p</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>b636870610</sourcerecordid><originalsourceid>FETCH-LOGICAL-a197t-d1651c5f7e47a267831a398c21507b653cc8efa26ed2db92ff73c598d0aca1d53</originalsourceid><addsrcrecordid>eNptkE1OwzAUhC0EoqWw4AIoGyS6CNh-cZMsSwQUqQIWsI4c_1BXSWzlp9AdV-AoXIRDcBKCAlmxeiO9T6OZQeiY4HOCKbkoHGAMELsdNCYsAD-CmO4OOgpG6KCu1xjTgFHYRyMKFAIKbIwWd7YUdsNzVTZeYguXq1feGFt6Vnvzwq1soyojTPn19n7pvZhm5T3YfHv2-eE_523DCyM8LoycHqI9zfNaHf3eCXq6vnpMFv7y_uY2mS99TuKw8SWZMSKYDlUQcjoLIyAc4khQwnCYzRgIESndfZSkMoup1iEIFkcSc8GJZDBB095XVLauK6VTV5mCV9uU4PRnjXRYo2NPeta1WaHkQP7V74DTHuCiTte2rcou-j9G3ynRZ-o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Noncovalent Complexation of Amphotericin‑B with Poly(α-glutamic acid)</title><source>MEDLINE</source><source>ACS Publications</source><creator>Mohamed-Ahmed, Abeer H. A ; Les, Karolina A ; Seifert, Karin ; Croft, Simon L ; Brocchini, Stephen</creator><creatorcontrib>Mohamed-Ahmed, Abeer H. A ; Les, Karolina A ; Seifert, Karin ; Croft, Simon L ; Brocchini, Stephen</creatorcontrib><description>A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20–50%. AmB was in a highly aggregated state with an aggregation ratio often above 2.0. This complex (AmB–PGA) was shown to be stable and to have reduced toxicity to human red blood cells and KB cells compared to the parent compound; cell viability was not affected at an AmB concentration as high as 50 and 200 μg/mL respectively. This AmB–PGA complex retained AmB activity against intracellular Leishmania major amastigotes in the differentiated THP-1 cells with an EC50 of 0.07 ± 0.03–0.08 ± 0.01 μg/mL, which is similar to Fungizone (EC50 of 0.06 ± 0.01 μg/mL). The in vitro antileishmanial activity of the complex against Leishmania donovani was retained after storage at 37 °C for 7 days in the form of a solution (EC50 of 0.27 ± 0.03 to 0.35 ± 0.04 μg/mL) and for 30 days as a solid (EC50 of 0.41 ± 0.07 to 0.63 ± 0.25 μg/mL). These encouraging results indicate that the AmB–PGA complex has the potential for further development.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/mp300339p</identifier><identifier>PMID: 23234235</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Amphotericin B - chemistry ; Amphotericin B - pharmacology ; Amphotericin B - therapeutic use ; Cell Line ; Glutamic Acid - chemistry ; Humans ; Leishmania donovani - drug effects ; Leishmania major - drug effects ; Leishmania major - pathogenicity ; Leishmaniasis - drug therapy ; Solubility</subject><ispartof>Molecular pharmaceutics, 2013-03, Vol.10 (3), p.940-950</ispartof><rights>Copyright © 2012 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a197t-d1651c5f7e47a267831a398c21507b653cc8efa26ed2db92ff73c598d0aca1d53</citedby><cites>FETCH-LOGICAL-a197t-d1651c5f7e47a267831a398c21507b653cc8efa26ed2db92ff73c598d0aca1d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/mp300339p$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/mp300339p$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2764,27075,27923,27924,56737,56787</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23234235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohamed-Ahmed, Abeer H. A</creatorcontrib><creatorcontrib>Les, Karolina A</creatorcontrib><creatorcontrib>Seifert, Karin</creatorcontrib><creatorcontrib>Croft, Simon L</creatorcontrib><creatorcontrib>Brocchini, Stephen</creatorcontrib><title>Noncovalent Complexation of Amphotericin‑B with Poly(α-glutamic acid)</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20–50%. AmB was in a highly aggregated state with an aggregation ratio often above 2.0. This complex (AmB–PGA) was shown to be stable and to have reduced toxicity to human red blood cells and KB cells compared to the parent compound; cell viability was not affected at an AmB concentration as high as 50 and 200 μg/mL respectively. This AmB–PGA complex retained AmB activity against intracellular Leishmania major amastigotes in the differentiated THP-1 cells with an EC50 of 0.07 ± 0.03–0.08 ± 0.01 μg/mL, which is similar to Fungizone (EC50 of 0.06 ± 0.01 μg/mL). The in vitro antileishmanial activity of the complex against Leishmania donovani was retained after storage at 37 °C for 7 days in the form of a solution (EC50 of 0.27 ± 0.03 to 0.35 ± 0.04 μg/mL) and for 30 days as a solid (EC50 of 0.41 ± 0.07 to 0.63 ± 0.25 μg/mL). These encouraging results indicate that the AmB–PGA complex has the potential for further development.</description><subject>Amphotericin B - chemistry</subject><subject>Amphotericin B - pharmacology</subject><subject>Amphotericin B - therapeutic use</subject><subject>Cell Line</subject><subject>Glutamic Acid - chemistry</subject><subject>Humans</subject><subject>Leishmania donovani - drug effects</subject><subject>Leishmania major - drug effects</subject><subject>Leishmania major - pathogenicity</subject><subject>Leishmaniasis - drug therapy</subject><subject>Solubility</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkE1OwzAUhC0EoqWw4AIoGyS6CNh-cZMsSwQUqQIWsI4c_1BXSWzlp9AdV-AoXIRDcBKCAlmxeiO9T6OZQeiY4HOCKbkoHGAMELsdNCYsAD-CmO4OOgpG6KCu1xjTgFHYRyMKFAIKbIwWd7YUdsNzVTZeYguXq1feGFt6Vnvzwq1soyojTPn19n7pvZhm5T3YfHv2-eE_523DCyM8LoycHqI9zfNaHf3eCXq6vnpMFv7y_uY2mS99TuKw8SWZMSKYDlUQcjoLIyAc4khQwnCYzRgIESndfZSkMoup1iEIFkcSc8GJZDBB095XVLauK6VTV5mCV9uU4PRnjXRYo2NPeta1WaHkQP7V74DTHuCiTte2rcou-j9G3ynRZ-o</recordid><startdate>20130304</startdate><enddate>20130304</enddate><creator>Mohamed-Ahmed, Abeer H. A</creator><creator>Les, Karolina A</creator><creator>Seifert, Karin</creator><creator>Croft, Simon L</creator><creator>Brocchini, Stephen</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20130304</creationdate><title>Noncovalent Complexation of Amphotericin‑B with Poly(α-glutamic acid)</title><author>Mohamed-Ahmed, Abeer H. A ; Les, Karolina A ; Seifert, Karin ; Croft, Simon L ; Brocchini, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a197t-d1651c5f7e47a267831a398c21507b653cc8efa26ed2db92ff73c598d0aca1d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Amphotericin B - chemistry</topic><topic>Amphotericin B - pharmacology</topic><topic>Amphotericin B - therapeutic use</topic><topic>Cell Line</topic><topic>Glutamic Acid - chemistry</topic><topic>Humans</topic><topic>Leishmania donovani - drug effects</topic><topic>Leishmania major - drug effects</topic><topic>Leishmania major - pathogenicity</topic><topic>Leishmaniasis - drug therapy</topic><topic>Solubility</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohamed-Ahmed, Abeer H. A</creatorcontrib><creatorcontrib>Les, Karolina A</creatorcontrib><creatorcontrib>Seifert, Karin</creatorcontrib><creatorcontrib>Croft, Simon L</creatorcontrib><creatorcontrib>Brocchini, Stephen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohamed-Ahmed, Abeer H. A</au><au>Les, Karolina A</au><au>Seifert, Karin</au><au>Croft, Simon L</au><au>Brocchini, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Noncovalent Complexation of Amphotericin‑B with Poly(α-glutamic acid)</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2013-03-04</date><risdate>2013</risdate><volume>10</volume><issue>3</issue><spage>940</spage><epage>950</epage><pages>940-950</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20–50%. AmB was in a highly aggregated state with an aggregation ratio often above 2.0. This complex (AmB–PGA) was shown to be stable and to have reduced toxicity to human red blood cells and KB cells compared to the parent compound; cell viability was not affected at an AmB concentration as high as 50 and 200 μg/mL respectively. This AmB–PGA complex retained AmB activity against intracellular Leishmania major amastigotes in the differentiated THP-1 cells with an EC50 of 0.07 ± 0.03–0.08 ± 0.01 μg/mL, which is similar to Fungizone (EC50 of 0.06 ± 0.01 μg/mL). The in vitro antileishmanial activity of the complex against Leishmania donovani was retained after storage at 37 °C for 7 days in the form of a solution (EC50 of 0.27 ± 0.03 to 0.35 ± 0.04 μg/mL) and for 30 days as a solid (EC50 of 0.41 ± 0.07 to 0.63 ± 0.25 μg/mL). These encouraging results indicate that the AmB–PGA complex has the potential for further development.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>23234235</pmid><doi>10.1021/mp300339p</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1543-8384
ispartof Molecular pharmaceutics, 2013-03, Vol.10 (3), p.940-950
issn 1543-8384
1543-8392
language eng
recordid cdi_crossref_primary_10_1021_mp300339p
source MEDLINE; ACS Publications
subjects Amphotericin B - chemistry
Amphotericin B - pharmacology
Amphotericin B - therapeutic use
Cell Line
Glutamic Acid - chemistry
Humans
Leishmania donovani - drug effects
Leishmania major - drug effects
Leishmania major - pathogenicity
Leishmaniasis - drug therapy
Solubility
title Noncovalent Complexation of Amphotericin‑B with Poly(α-glutamic acid)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A43%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Noncovalent%20Complexation%20of%20Amphotericin%E2%80%91B%20with%20Poly(%CE%B1-glutamic%20acid)&rft.jtitle=Molecular%20pharmaceutics&rft.au=Mohamed-Ahmed,%20Abeer%20H.%20A&rft.date=2013-03-04&rft.volume=10&rft.issue=3&rft.spage=940&rft.epage=950&rft.pages=940-950&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/mp300339p&rft_dat=%3Cacs_cross%3Eb636870610%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23234235&rfr_iscdi=true